在实验性充血性心力衰竭中增强心脏心脏特洛芬-1
M Jougasaki1, I Tachibana, A Luchner
1Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN 55905, USA. jougasaki@mayo.edu
Circulation
|January 5, 2000
概括
心脏增生蛋白-1 (CT-1) 在实验性心力衰竭中升高调节,与左心室缩相关. 这表明CT-1在充血性心力衰竭 (CHF) 期间的心脏重塑中起着关键作用.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 进行心脏重塑.
背景情况:
- 心脏增生蛋白-1 (CT-1) 是一种强大的增生因子.
- 使用小鼠胚胎干细胞心脏发生模型发现.
研究的目的:
- 调查CT-1表达在节奏诱导的充血性心力衰竭 (CHF).
- 在CHF中确定CT-1和左心室缩之间的关系.
主要方法:
- 使用了一种犬类模型来进行刺激诱导的实验性CHF.
- 使用北方斑点分析和免疫组织化学来评估CT-1表达.
- 与左心室质量指数相关的心室CT-1mRNA.
主要成果:
- 在正常的心房和心室中检测到CT-1基因表达.
- 在CHF心脏中,CT-1表达显著增加.
- 心室CT-1mRNA与左心室质量呈正相关性.
- 在CHF心脏的心肌细胞中,CT-1免疫活性更强烈.
结论:
- 前庭和心室都合成CT-1.
- 在实验性CHF中,心脏CT-1产量增加.
- 室内CT-1mRNA与左室缩相关,表明在CHF结构重塑中发挥了作用.
相关概念视频
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


